SOURCE: Savara, Inc.

Savara, Inc.

January 04, 2018 08:00 ET

Savara Announces Appointment of Peter Ginsberg as Vice President of Business Development

AUSTIN, TX--(Marketwired - January 04, 2018) - Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Peter Ginsberg has joined the company as Vice President of Business Development. An accomplished orphan lung disease business development and investment executive, Mr. Ginsberg brings to Savara a wealth of experience in biopharma business development and strategic planning, in addition to a unique perspective as a former senior biotechnology analyst and healthcare institutional investor.

"We are incredibly pleased to have Peter join our team at this pivotal time in the company's development," stated Taneli Jouhikainen, President and Chief Operating Officer of Savara. "Peter has an impressive track record of generating growth through business development transactions and devising corporate strategy with a specific focus on orphan lung disease opportunities. We see this as a perfect match to Savara's next phase of development and growth."

Most recently, Mr. Ginsberg served as Vice President of Business Development for BioDelivery Sciences International (NASDAQ: BDSI). Prior to that, Mr. Ginsberg headed business development for United Therapeutics Corporation, where he led the sale of its Priority Review Voucher for $350 million. Previously, Mr. Ginsberg was responsible for acquisitions and licensing as Vice President of Business Development and Strategic Planning for SurModics, and he also spent 15 years in the healthcare investment industry, during which time he was named a Wall Street Journal All-Star as Piper Jaffray's lead biotechnology analyst where his coverage focused heavily on pulmonary drug delivery companies. He earned an A.B. from Princeton University, an M.B.A. from the Tuck School of Business at Dartmouth College, and is a Chartered Financial Analyst®. In addition, Mr. Ginsberg acts as a reviewer for the National Heart, Lung, and Blood Institute (NHLBI).

About Savara
Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara's pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for pulmonary alveolar proteinosis, or PAP, and in preparation for Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection; AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in Cystic Fibrosis; and, Aironite, an inhaled sodium nitrite for heart failure with preserved ejection fraction, or HFpEF, in Phase 2 development. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)

Forward Looking Statements
Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements relating to our growth and development, our view that Mr. Ginsberg's background is a perfect match to Savara's next phase of development and growth, and our strategy. Savara may not actually achieve any of the matters referred to in such forward looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Savara's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the outcome of our ongoing clinical trials for our product candidates, the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara's operations and to conduct or continue planned clinical development programs, the ability to obtain the necessary patient enrollment for our product candidates in a timely manner, the ability to successfully develop our product candidates, the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates such as Molgradex, AeroVanc and Aironite that are safe and effective for use as human therapeutics and the timing and ability of Savara to raise additional equity capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

Contact Information